gms | German Medical Science

81. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie e. V.

12.05. - 16.05.2010, Wiesbaden

Prognostic Relevance of Lysyl Oxidase-Expression in Oral and Oropharyngeal Squamous Cell Carcinoma (OSCC)

Meeting Abstract

  • corresponding author Andrea Albinger - ORL Klinik Zürich, Switzerland
  • Ivan Hegyi - Department of Dermatolgy, Inselspital Bern, Switzerland
  • Sandro Stöckli - Clinic of Otorhinolaryngology, Head and Neck Surgery, Kantonsspital St. Gallen, Switzerland
  • Stephan Schmid - Clinic Bethanien, Zürich, Switzerland
  • Holger Moch - Department Pathology, Institute of Surgical Pathology, University Hospital Zürich, Switzerland

Deutsche Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. 81. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie. Wiesbaden, 12.-16.05.2010. Düsseldorf: German Medical Science GMS Publishing House; 2010. Doc10hnod127

doi: 10.3205/10hnod127, urn:nbn:de:0183-10hnod1278

Veröffentlicht: 22. April 2010

© 2010 Albinger et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen ( Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.



Introduction: Hypoxia, the inadaquate supply of blood borne oxygen, was identified as a marker of an aggressive tumour phenotype and malignant progression. Hypoxia is associated with a poor tumour response to radiotherapy, to some chemotherapeutic agents, as well as poor outcome following surgery. Pathways regulated by hypoxia include: tissue invasion, metastasis, genetic instability, apoptosis, immortalization, angiogenesis, growth factor signalling and pH regulation3.

Lysyl oxidase (LOX) is a copper-dependent metalloenzyme. Recently LOX was validated as a hypoxia-responsive gene regulated by hypoxia-inducible factor-1. Conflicting data were published so far, regarding the expression and significance of LOX in head and neck squamous cell carcinoma.

Methods: We have analysed 252 patientens: 92 with, 160 without lymph node metastases with tissue microarrays (TMA). TMA was constructed according to standard protocols.

Results: Correlation of the LOX-Expression with the clinicopathological patient characteristics.

High LOX-expression shows a significant correlation with the presence of lymph node disease (P=0.001) in the entire patient cohort, as well as for patients with small primary tumors (T1 und T2) (P=0.001).

Kaplan-Meier plot.

OSCC patients with high LOX-expression have significantly shortened overall and disease free survival (P=0.004 und P=0.038).

Conclusion: The univariate analysis revealed correlation between overall survival and the T-stadium (P=0.000), N-stadium (P=0.012),as well as the LOX-Expression (P=0.004). Tumor T-stadium (P=0.000) as well as the high LOX-expression (P=0.044) were indentified in the Cox-regression modell as independent negative prognostic factors for the overall survival.